Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Obesity
Biotech
Arch-backed obesity biotech launches with $290M
Clinical-stage Metsera has emerged from stealth with $290 million and the bold vision of ushering in the next generation of obesity treatments.
Gabrielle Masson
Apr 18, 2024 7:00am
A look at the R&D landscape in obesity, led by GLP-1s
Mar 19, 2024 8:00am
Another win for Novo in obesity as early oral med beats Wegovy
Mar 7, 2024 9:27am
Lindus hops on GLP-1 hype with CRO service for metabolic disease
Mar 6, 2024 12:45pm
Amgen's obesity drug may help patients keep the weight off
Feb 7, 2024 10:40am
Novo Nordisk advances obesity pill as R&D spend skyrockets 35%
Jan 31, 2024 9:44am